RCKT Share Price | Rocket Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: What does Rocket Pharmaceuticals, Inc. do?

Overview: Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing gene therapy treatment options for rare, devastating diseases within the Pharmaceuticals & Biotechnology industry, categorized as a small-cap company.Financial Snapshot: Net Profit: -61 Million (Quarterly Results - Mar 2025) Market cap: USD 293.05 Million (Small Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.77 Return on Equity: -62.77% Price to Book: 0.71Contact Details: Address: 350 5th Ave Ste 7530, NEW YORK NY: 10118-7501 Tel: 1 646 4409100 Fax: 1 781 6762155 Website: https://www.rocketpharma.com/

Q: Is Rocket Pharmaceuticals, Inc. technically bullish or bearish?

As of 11 August 2025, the technical trend for Rocket Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands indicate a mildly bearish stance weekly and bearish monthly. Daily moving averages are mildly bearish, and the KST reflects a mildly bullish trend weekly but bearish monthly. According to Dow Theory, there is a mildly bearish trend on the weekly chart with no trend on the monthly.In terms of performance, Rocket Pharmaceuticals has underperformed the S&P 500 significantly over multiple periods, with a year-to-date return of -74.78% compared to the S&P 500's 12.22%, and a one-year return of -84.79% versus 17.14% for the index. Overall, the current technical stance is mildly bearish.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.25 M

Shareholding (Dec 2025)

FII

13.19%

Held by 122 FIIs

DII

48.8%

Held by 49 DIIs

Promoter

4.16%

How big is Rocket Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Rocket Pharmaceuticals, Inc. has a market capitalization of 293.05 million and reported net sales of 0.00 million with a net profit of -258.03 million over the latest four quarters. Shareholder's funds are 463.23 million, and total assets amount to 527.70 million.

View full answer

What does Rocket Pharmaceuticals, Inc. do?

22-Jun-2025

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare diseases, with a market cap of approximately $293 million and a net profit of -$61 million as of March 2025. The company has no dividend yield and negative financial metrics, indicating it is currently loss-making.

View full answer

Who are in the management team of Rocket Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Rocket Pharmaceuticals, Inc. includes Dr. Roderick Wong (Chairman), Dr. Gaurav Shah (CEO), and several independent directors: Mr. David Southwell, Dr. Elisabeth Bjork, Mr. Carsten Boess, Mr. Pedro Granadillo, and Dr. Gotham Makker. They oversee the company's strategic direction and operations.

View full answer

Is Rocket Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of August 11, 2025, Rocket Pharmaceuticals, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly year-to-date and over the past year.

View full answer

Compare Rocket Pharmaceuticals, Inc. with Similar Stocks

Arcellx, Inc.Beam Therapeutics, Inc.Ventyx Biosciences, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 529 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.70

Return on Equity

-75.66%

Price to Book

1.69

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-43 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

33.33%

6 Months

40.96%

1 Year

-46.39%

2 Years

-82.8%

3 Years

-71.93%

4 Years

-70.79%

5 Years

-89.88%

Rocket Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-190.83%

EBIT to Interest (avg)

-96.76

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.77

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.69

EV to EBIT

-1.25

EV to EBITDA

-1.31

EV to Capital Employed

3.29

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-263.45%

ROE (Latest)

-75.66%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 55 Schemes (33.82%)

Foreign Institutions

Held by 122 Foreign Institutions (13.19%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 29.52% vs -1.01% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-41.80",
          "val2": "-60.30",
          "chgp": "30.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.50",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-42.50",
          "val2": "-60.30",
          "chgp": "29.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 13.76% vs -5.33% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-217.50",
          "val2": "-263.80",
          "chgp": "17.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.90",
          "val2": "1.90",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.30",
          "val2": "-1.90",
          "chgp": "-73.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-223.10",
          "val2": "-258.70",
          "chgp": "13.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-41.80

-60.30

30.68%

Interest

0.50

Exceptional Items

0.00

-0.00

Consolidate Net Profit

-42.50

-60.30

29.52%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 29.52% vs -1.01% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-217.50

-263.80

17.55%

Interest

1.90

Exceptional Items

-3.30

-1.90

-73.68%

Consolidate Net Profit

-223.10

-258.70

13.76%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 13.76% vs -5.33% in Dec 2024

All Annual Results

Company CV

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer. Its additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). The Company is also developing an AAV-based gene therapy program for pediatric heart failure indication, Danon disease.

Company Coordinates

Company Details

350 5th Ave Ste 7530 , NEW YORK NY : 10118-7501

Tel: 1 646 4409100

https://www.rocketpharma.com/

Registrar Details